Literature DB >> 21737561

Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study.

C R Jenkins1, B Celli, J A Anderson, G T Ferguson, P W Jones, J Vestbo, J C Yates, P M A Calverley.   

Abstract

We investigated the impact of season relative to other determinants of chronic obstructive pulmonary disease (COPD) exacerbation frequency in a long-term international study of patients with forced expiratory volume in 1 s (FEV(1)) <60% predicted. COPD exacerbations were defined by worsening symptoms requiring systemic corticosteroids and/or antibiotics (moderate) or hospital admission (severe). Seasonality effect was calculated as the proportion of patients experiencing an exacerbation each month. Exacerbations in the northern and southern regions showed an almost two-fold increase in the winter months. No seasonal pattern occurred in the tropics. Overall, 38% of exacerbations were treated with antibiotics only, 19% with systemic corticosteroids only and 43% with both, while 20% required hospital admission irrespective of the season. Exacerbation frequency was associated with older age, lower body mass index, lower FEV(1) % pred and history of prior exacerbations. Females and patients with worse baseline breathlessness, assessed using the Medical Research Council (MRC) dyspnoea scale, exacerbated more often (rate ratio (RR) for male versus female 0.7, 95% CI 0.7-0.8 (p<0.001); RR for MRC dyspnoea score 3 versus 1 and 2 combined 1.1, 95% CI 1.1-1.2 (p<0.001)). The effect of season was independent of these risk factors. COPD exacerbations and hospitalisations were more frequent in winter.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21737561     DOI: 10.1183/09031936.00194610

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  86 in total

1.  Detecting COPD exacerbations early using daily telemonitoring of symptoms and k-means clustering: a pilot study.

Authors:  Daniel Sanchez-Morillo; Miguel Angel Fernandez-Granero; Antonio León Jiménez
Journal:  Med Biol Eng Comput       Date:  2015-03-01       Impact factor: 2.602

2.  Effectiveness of Umeclidinium-Vilanterol for Protocolized Management of Chronic Obstructive Pulmonary Disease Exacerbation in Hospitalized Patients: A Sequential Period Analysis.

Authors:  Todd W Chapin; Michael A Mann; Gary L Brown; Traci L Leitheiser; Becky Anderson; David D Leedahl
Journal:  Chronic Obstr Pulm Dis       Date:  2018-01-24

3.  Colder temperature is associated with increased COPD morbidity.

Authors:  Meredith C McCormack; Laura M Paulin; Christine E Gummerson; Roger D Peng; Gregory B Diette; Nadia N Hansel
Journal:  Eur Respir J       Date:  2017-06-29       Impact factor: 16.671

4.  Significance of Medication History at the Time of Entry into the COPDGene Study: Relationship with Exacerbation and CT Metrics.

Authors:  Seoung Ju Park; Barry Make; Craig P Hersh; Russell P Bowler
Journal:  COPD       Date:  2015-08       Impact factor: 2.409

5.  Effectiveness of pharmaceutical care for patients with chronic obstructive pulmonary disease (PHARMACOP): a randomized controlled trial.

Authors:  Eline Tommelein; Els Mehuys; Thierry Van Hees; Els Adriaens; Luc Van Bortel; Thierry Christiaens; Inge Van Tongelen; Jean-Paul Remon; Koen Boussery; Guy Brusselle
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

6.  The effect of the weather on pulmonary exacerbations and viral infections among adults with cystic fibrosis.

Authors:  W G Flight; R J Bright-Thomas; C Sarran; K J Mutton; J Morris; A K Webb; A M Jones
Journal:  Int J Biometeorol       Date:  2014-01-23       Impact factor: 3.787

7.  Seasonal and Regional Variations in Chronic Obstructive Pulmonary Disease Exacerbation Rates in Adults without Cardiovascular Risk Factors.

Authors:  Jennifer Y So; Huaqing Zhao; Helen Voelker; Robert M Reed; Donald Sin; Nathaniel Marchetti; Gerard J Criner
Journal:  Ann Am Thorac Soc       Date:  2018-11

8.  Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD.

Authors:  David M Mannino; Ruth Tal-Singer; David A Lomas; Jorgen Vestbo; R Graham Barr; Kay Tetzlaff; Michael Lowings; Stephen I Rennard; Jeffrey Snyder; Mitchell Goldman; Ubaldo J Martin; Deborah Merrill; Amber L Martin; Jason C Simeone; Kyle Fahrbach; Brian Murphy; Nancy Leidy; Bruce Miller
Journal:  Chronic Obstr Pulm Dis       Date:  2015

Review 9.  Combined corticosteroid and long-acting beta₂-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease.

Authors:  Luis Javier Nannini; Phillippa Poole; Stephen J Milan; Rebecca Holmes; Rebecca Normansell
Journal:  Cochrane Database Syst Rev       Date:  2013-11-10

10.  Cost-effectiveness of indacaterol/glycopyrronium in comparison with salmeterol/fluticasone combination for patients with moderate-to-severe chronic obstructive pulmonary disease: a LANTERN population analysis from Singapore.

Authors:  Augustine Tee; Wai Leng Chow; Colin Burke; Basavarajaiah Guruprasad
Journal:  Singapore Med J       Date:  2018-03-16       Impact factor: 1.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.